OrPro Therapeutics, Inc. (San Diego) announced that the company has been awarded a National Heart, Lung and Blood Institute Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).
The grant enables OrPro to advance development of its lead product, ORP-100, for the treatment of cystic fibrosis (CF), an inherited genetic disease that affects approximately 80,000 people worldwide. The mucolytic properties of thioredoxin were discovered at leading respiratory hospital National Jewish Health (NJH) in Denver, CO by pediatric pulmonologist Dr. Carl White, M.D. In 2011, OrPro licensed from NJH an intellectual property portfolio claiming compositions and uses of the thioredoxin active site for the treatment of pulmonary disease. Dr. White (now at University of Colorado Denver/Children's Hospital Colorado), and his NJH colleague Dr. David Nichols are medical advisors to the company, and will collaborate on the NIH-funded project.
Go Back
